In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

While the launch of Wegovy affirms the company’s ability to address emerging challenges in obesity, it has also moved to strengthen its prospects with weight loss treatment CagriSema.

In late December, Novo Nordisk announced that its much anticipated next-generation obesity drug CagriSema had missed its target for patients to lose 25 per cent of their body weight in a late ...

Before you jump in, however, it's crucial to understand the difference between collagen and collagen peptides -- because, yes, there is a difference. Here's everything you need to know.